MRI Reveals Joint Damage After Cancer Treatment
According to a UK study, whole-body MRI showed that patients with arthralgia who had previously received immune checkpoint inhibitor therapy had similar levels of inflammation and erosions as those with clinical arthritis, with distinct imaging patterns.
METHODOLOGY:
Researchers recruited 60 adults (mean age, 65 years; 43% women; 100% White) with new musculoskeletal symptoms during or within 6 months after receiving treatment with immune checkpoint inhibitors and 20 healthy control individuals (mean age, 62 years; 40% women; 100% White) from the UK, who underwent gadolinium contrast-enhanced whole-body MRI.
A total of 35 patients had arthralgia and 25 had inflammatory arthritis.
Two independent masked assessors graded joint, tendon, bursal, entheseal, and whole spinal imaging lesions, with consensus reporting and a 6-month follow-up.
TAKEAWAY:
Distinct global inflammatory patterns were identified on the MRI scans: polymyalgia rheumatica (extracapsular; 12%), peripheral inflammatory arthritis (37%), spondyloarthropathy (n = 1), and a non-specific pattern (20%).
Median total appendicular joint synovitis, joint erosion, enthesitis, and tenosynovitis scores were significantly higher in both arthralgia and inflammatory arthritis groups than in control individuals, with no significant differences found between the arthralgia and inflammatory arthritis subgroups.
Among the patients exposed to immune checkpoint inhibitors, acromioclavicular (77%), glenohumeral (75%), wrist (73%), and metacarpophalangeal (59%) joints were most frequently affected by synovitis.
Patients with a peripheral inflammatory arthritis pattern were most likely to require disease-modifying antirheumatic drug therapy, showing the highest initial and ongoing glucocorticoid requirement.
IN PRACTICE:
"[The study] results suggest that the overall burden of musculoskeletal toxicity associated with immune checkpoint inhibitors is currently under-recognised and highlights the range and extent of inflammation in all patients presenting with new musculoskeletal symptoms after exposure to an immune checkpoint inhibitor. Rheumatology assessment should be considered by oncologists for patients who develop arthralgia alone," the authors wrote.
SOURCE:
This study was led by Kate Harnden, MBChB, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, England. It was published online on June 10, 2025, in The Lancet Rheumatology.
LIMITATIONS:
Feet and ankles were not imaged during the study due to logistical constraints. The 6-month follow-up period was relatively short for determining long-term musculoskeletal outcomes. Some patients were classified as having non-specific inflammation patterns, whose significance was unclear. A few participants had preexisting autoimmune diseases, possibly increasing their baseline risk for arthritis. Additionally, intra-assessor agreement was not measured.
DISCLOSURES:
This study received support from the National Institute for Health and Care Research Leeds Biomedical Research Centre. One author reported receiving a EULAR bursary travel award, and some authors reported having financial ties with various sources. Details are provided in the original article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
an hour ago
- Fox News
Three-person IVF technique shown to prevent inherited genetic diseases
An unconventional approach to reproduction is reportedly reducing the risk of metabolic disease. Three-person in vitro fertilization (IVF), a new concept developed by scientists in New Castle, U.K., has resulted in the births of eight healthy children. In the study, published in The New England Journal of Medicine, the researchers found that pathogenic variants in mitochondrial DNA (mtDNA) are a "common cause" of severe — and often fatal — inherited metabolic disease. This DNA in the mother's mitochondria can cause "harmful mutations" in children, which can lead to diseases that affect tissues in the heart, brain and muscles, according to the journal Nature. At the Newcastle Fertility Centre, 22 women with pathogenic mtDNA variants underwent a "pronuclear transfer," in which they received a mitochondrial donation. This involved the transfer of the nucleus of a fertilized egg with "faulty mitochondria" into a donor egg cell with healthy mitochondria, Nature detailed. The result includes nuclear DNA from both the biological mother and father, as well as mitochondrial DNA from the separate egg donor. From this, eight children were born healthy, with no levels or low levels of mtDNA detected in their blood. The researchers noted that one child did develop hyperlipidemia (high cholesterol) and cardiac arrhythmia (irregular heartbeat) — as the child's mother had hyperlipidemia during pregnancy — but both conditions responded to treatment. Another child developed infant myoclonic epilepsy — a rare type of epilepsy that typically affects infants between 6 months and 3 years old — which concluded in "spontaneous remission." "At the time of this report, all the children have made normal developmental progress," the researchers noted. Dr. Zev Williams, director of Columbia University Fertility Center in New York City, said this latest research "marks an important milestone." "Expanding the range of reproductive options … will empower more couples to pursue safe and healthy pregnancies," he said in an interview with Fox News Digital. In a press briefing, Robert McFarland, a pediatric neurologist at Newcastle University, who co-led one of the studies, reportedly noted the team's "cautious optimism" about the results. "To see babies born at the end of this is amazing, and to know there's not going to be mitochondrial disease at the end of that," he said. Fox News Digital reached out to the study researchers for comment.
Yahoo
an hour ago
- Yahoo
This Handwriting Change May Be An Early Sign Of Parkinson's
Parkinson's disease, the condition Ozzy Osborne was diagnosed with roughly five years before his death, affects about 153,000 people in the UK at the moment. It is a progressive neurological disease. While there is no single, outright cure for it yet, the NHS says therapies like medication and physiotherapy can minimise its symptoms for many. But sadly, the condition is often misdiagnosed, even though early diagnosis can be very beneficial. That's why organisations like Parkinson's UK champion better, earlier diagnoses, and hope one day for a single test that can accurately spot the disease as soon as possible. In the meantime, however, they've shared early signs of the condition; one of which involves changes to your handwriting. How is handwriting linked to Parkinson's? Parkinson's UK says that noticing smaller handwriting over time is one potential early sign. This is called micrographia, and could affect as many as 50-60% of people living with Parkinson's, though the numbers are not settled. 'You may notice the way you write words on a page has changed, such as letter sizes are smaller and the words are crowded together,' the charity shared. A 2022 paper suggested that the handwriting change may precede other motor symptoms of Parkinson's, like tremors. Parkinson's is not the only cause of handwriting changes – it's been linked to other neurological changes, while Parkinson's UK says 'writing can change as you get older, if you have stiff hands or fingers or poor vision' – but it may be worth seeing your doctor about it, especially if it comes with other symptoms. What are the other early symptoms of Parkinson's? According to Parkinson's UK, having a single early symptom doesn't mean you've got the disorder. But 'if you have more than one sign, you should consider making an appointment to talk to your doctor,' they wrote. Aside from micographia, the other possible symptoms they listed were: Tremors. Shaking in your finger, thumb, hand, or chin while at rest is a common early symptom. Loss of smell, especially for strongly-scented foods like bananas, liquorice, and gherkins. Moving a lot in your sleep, especially if you start acting out your dreams or thrashing around a lot. Trouble with movement or walking. You might find your arms don't swing as much as they used to when you walk, that your limbs or stiff, that your shoulders of hips feel tight, or that your feet feel 'stuck to the floor.' Constipation. This can be normal, but it can persist with Parkinson's. Developing a soft, low voice that others might describe as hoarse or breathy and which might sound quieter than usual. 'Facial masking,′ or a sad or angry expression on your face that happens regardless of your mood. Dizziness or fainting, for instance, when getting up out of a chair – this can be linked to low blood pressure, which is associated with Parkinson's. Stooping or hunching over, especially if this is new for you. Related... 'Super Smeller' Inspires Test To Spot Parkinson's 7 Years Before Diagnosis Gut Health Discovery Could Help Future Parkinson's Diagnoses Parkinson's Cases Are Set To Double By 2050. Here Are 5 Early Signs To Watch For
Forbes
an hour ago
- Forbes
Turkey Legalizes Medical Cannabis Sales In Pharmacies
A technician inspects the leaves of cannabis plants growing inside a controlled environment in North ... More Macedonia. Photographer: Konstantinos Tsakalidis/Bloomberg Turkey has passed a landmark bill that legalizes the sale of cannabis products for medical use in pharmacies, marking a step forward in expanding patient access to such treatment. The Turkish Parliament this week approved a bill that allows the sale of cannabis-based products in pharmacies with a prescription. The bill, introduced by the Justice and Development Party (AK Party), led by President Recep Tayyip Erdoğan, published in the Official Gazette yesterday, regulates access to medical cannabis products that are non-intoxicating and low in THC, such as those containing CBD. It amended a number of laws, including the narcotics law and regulations related to pharmacies and shops that sell poisonous or effective chemical substances. These regulations reportedly aim to meet healthcare needs through domestic production, reduce dependence on imports, and prevent the use of unregistered products. The changes, therefore, are expected to boost the legal production of low-THC medical cannabis in Turkey. Under the new rules, the cultivation of medical cannabis will be supervised by the Ministry of Agriculture and Forestry, while processing, export, licensing, registration, and authorization for sale will fall under the oversight of the Ministry of Health. By amending the narcotics law, medical cannabis products will now be available through pharmacies. Furthermore, each product will be tracked from production or import all the way to patient use through a centralized tracking system designed to block counterfeit, smuggled, or unauthorized products from entering the legal market. The law limits medical cannabis sales to pharmacies in order to block access through unregulated retail and online markets, with the aim to protect public health and ensure product safety. Concerns Over Medical Cannabis Bill Before the bill became law, the Turkish Medical Association (TTB) criticized the proposed cannabis regulation, arguing that there is not enough scientific evidence to support the medical benefits of cannabis and warned that its widespread use could lead to serious physical and mental health risks. In December 2020, the UN Commission on Narcotic Drugs (CND), the United Nations' drug policy-making body, reclassified cannabis and cannabis resin under an international category that acknowledges their medical value. The association also urged lawmakers to remove the cannabis-related measures from the bill, which has also faced criticism from members of some opposition parties. While the new law will allow people to purchase low-THC medical cannabis products from pharmacies, easing access for treatment, cannabis remains illegal in Turkey for recreational use. In 2016, legislation allowed the use of sublingual cannabinoid medications, such as Sativex, with a doctor's prescription. The new law, however, is expected to make it easier for medical cannabis patients to obtain cannabis products from pharmacies with a prescription. This reform is also viewed as a significant step toward supporting Turkey's entry into the cannabis-based product market and boosting its international competitiveness. Turkey is, in fact, not new to cannabis cultivation, particularly hemp, which is legal in several provinces for medical and scientific purposes. According to data from TurkStat, compiled by the state-run Anadolu news agency, Turkey's cannabis seed production surged about 70% year-on-year in 2024, reaching 556 tons, up from 273 tons in 2020. Turkey now joins other European countries where medical cannabis is legal, such as Italy and Germany, which, however, allow products with higher levels of THC. Ukraine has also recently legalized medical cannabis.
